SOP for Conducting Stability Studies for Novel Excipient-Drug Combinations in Compliance with Regulatory Guidelines

Procedure for Stability Testing of Novel Excipient-Drug Combinations

1) Purpose

The purpose of this SOP is to outline the procedure for conducting stability studies for drug products containing novel excipient-drug combinations in compliance with relevant regulatory guidelines. This ensures that the novel combination maintains its quality, safety, and efficacy throughout its shelf life.

2) Scope

This SOP applies to all personnel involved in the stability testing of drug products containing novel excipients, including formulation development, quality control, and regulatory affairs teams.

3) Responsibilities

Formulation Development Team: Responsible for developing formulations that incorporate novel excipients and selecting suitable packaging materials.
Stability Study Team: Responsible for conducting stability studies according to approved protocols.
Regulatory Affairs Team: Responsible for ensuring compliance with regulatory guidelines and submitting stability data to authorities.

4) Procedure

4.1 Protocol Development

4.1.1 Develop a stability testing protocol that addresses potential interactions between the

novel excipient and active ingredient, including assay, dissolution, and degradation products.

4.1.2 Define storage conditions (e.g., room temperature, accelerated) and testing intervals (e.g., 0, 3, 6, 12 months) based on regulatory guidelines.

4.2 Sample Preparation and Storage

4.2.1 Prepare samples in their final packaging for stability testing, ensuring uniformity and consistency throughout the study.

4.2.2 Store

samples under specified conditions as per the protocol, with continuous monitoring of storage environments.

4.3 Conducting Stability Tests

4.3.1 Perform stability tests at all required intervals, focusing on the impact of the novel excipient on the drug’s stability and performance.

4.3.2 Document all data accurately and ensure compliance with the approved protocol.

4.4 Data Analysis and Reporting

4.4.1 Analyze stability data to identify any trends, deviations, or incompatibilities between the excipient and the active ingredient.

4.4.2 Prepare a comprehensive stability report for regulatory submission, detailing all findings and conclusions.

5) Abbreviations, if any

QA: Quality Assurance

6) Documents, if any

6.1 Stability testing protocols
6.2 Data sheets
6.3 Stability reports

7) Reference, if any

FDA Guidance for Industry: Stability Testing of Novel Excipient-Drug Combinations

8) SOP Version

Version 1.0